

Special Issue

Nanotechnology for Precision Delivery of Therapeutic and Imaging Agents – A Theranostic Approach

Message from the Guest Editor

Theranostic nanomedicine is an emerging field that combines the unique capabilities of nanotechnology with personalized medicine. The term “theranostics” was coined by combining diagnostic and therapeutic capabilities into a single agent. Over the last decade, researchers have investigated nanoparticle-based imaging and therapy separately, and only recently has the focus changed to NP-based theranostics. Even with the recent success of nanoparticles for the treatment of COVID-19, nanoparticle-based imaging and therapy are each struggling to advance into clinical trials. At the same time, nanoparticle-based theranostics are still in their early stages of development. This Special Issue will provide insights into new drug delivery or imaging nanoparticles that could evolve into nanotheranostic platforms. Original research and reviews in the issue will focus on preclinical applications of delivery of therapeutic payloads and/or diagnostic probes in the context of cancer, cardiovascular and pulmonary diseases, and regenerative medicine.

Guest Editor

Dr. Miguel Filipe Moreira Ferreira
Massachusetts General Hospital, 149 Thirteenth Street, Charlestown,
MA 02129, USA

Deadline for manuscript submissions

closed (10 April 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 12.5
Indexed in PubMed



mdpi.com/si/101004

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 12.5
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).